PeriCor Therapeutics Mourns the Loss of Ross Dixon, Ph.D., Vice President, Pharmaceutical Development Welcome to PeriCor Therapeutics PeriCor Therapeutics, Inc is a private, clinical-stage specialty biopharmaceutical company focused on developing novel therapies to prevent the morbidity and mortality caused by myocardial injury. PeriCor Therapeutics is a leader in the development and commercialization of a new class of medicines known as adenosine regulating agents (ARAs). ARAs amplify the body's own protective response to ischemia and reperfusion injury, the tissue damage that occurs even after interrupted blood flow is restored. They operate in a highly targeted manner by increasing the amount of protective adenosine only in affected tissues. By preventing or limiting reperfusion injury, this class of compounds has been shown to reduce the perioperative complications of surgery and promises to improve the treatment and outcomes of acute cardiovascular care. Our lead compound, acadesine, has been studied in five placebo-controlled clinical trials of patients undergoing coronary artery bypass graft (CABG) surgery that enrolled more than 4, 000 patients. This clinical experience documents a remarkable safety profile of this mechanistic approach to cardioprotection. In August 2007, we granted a license to Schering Plough Corporation for global development and commercialization rights to acadesine. Schering-Plough will conduct a confirmatory Phase III trial with acadesine in CABG surgery to confirm its safety and efficacy in reducing the incidence of death, severe left ventricular dysfunction, and stroke. Our three next generation ARA compounds are structural analogues of acadesine, each of which exhibits more potent adenosine-mediated, cardioprotective activity than acadesine. The safety of these compounds has been evaluated in Phase I clinical trials. These compounds show promise of providing cardioprotective clinical benefit to patients in surgical settings beyond CABG surgery and in acute cardiovascular settings. We have an open IND for GP531 that has been shown in preclinical models to possess more potent cardioprotective activity than acadesine. We have initiated preclinical evaluation of this novel compound beyond ischemia-reperfusion injury, and if successful, we will initiate Phase II clinical studies with this compound in 2009. PeriCor Therapeutics was incorporated in March 2004 and began operations in February 2005 with offices in New York, NY.